Literature DB >> 17457611

Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.

Xiao-Yong Pu1, Xing-Huan Wang, Yi-Long Wu, Huai-Peng Wang.   

Abstract

PURPOSE: To comparatively evaluate the effect of 3- versus 8-month neoadjuvant hormonal therapy (NHT) on laparoscopic radical prostatectomy (LRP) operative and postoperative parameters.
METHODS: We evaluated 55 patients with clinically localized prostate cancer treated by 3-month (25 patients, group-1), 8-month NHT (19 patients, group-2) and non-neoadjuvant therapy (11 patients, group-3) before LRP. Serum PSA levels and prostate volume were measured and evaluated monthly before operation. The operative and postoperative parameters were recorded and compared in the three different groups.
RESULTS: Transrectal ultrasound determined that prostate volume decreased 39.6% in group 1 and 35.4% in group 2 after 3-month NHT and a further 34.4% in group 2 after 8-month NHT. The mean prostate volume was significantly smaller after 8-month than 3-month NHT in group 2 (P < 0.05). Mean serum PSA decreased 97.8% in group 1 and 98.1% in group 2 after 3-month NHT. A further 72.9% PSA decrease was determined after 8-month NHT in group 2. There were no significant differences in the three groups with respect to mean operative time, mean blood loss, transfusion rate, operative difficulty, catheterization time, hospital time and complication rate (P > 0.05, respectively). Positive margin rate was significantly lower in the 3- or 8-month NHT group than in the non-adjuvant group (P < 0.05, respectively). However, there was no significant difference between the 3- and 8-month groups with respect to positive margin rate (P > 0.05).
CONCLUSIONS: The prolonged NHT (8-month) did not affect the operative or postoperative parameters. The LRP can be safely performed in patients after prolonged NHT. Prospective randomized studies are required to determine whether prolonged NHT reduces the risk of biochemical recurrence after LRP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457611     DOI: 10.1007/s00432-007-0204-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.

Authors:  L H Klotz; S L Goldenberg; M Jewett; J Barkin; M Chetner; Y Fradet; J Chin; S Laplante
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

2.  Heilbronn laparoscopic radical prostatectomy. Technique and results after 100 cases.

Authors:  J Rassweiler; L Sentker; O Seemann; M Hatzinger; C Stock; T Frede
Journal:  Eur Urol       Date:  2001-07       Impact factor: 20.096

3.  Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.

Authors:  M E Gleave; S L Goldenberg; J L Chin; J Warner; F Saad; L H Klotz; M Jewett; V Kassabian; M Chetner; C Dupont; S Van Rensselaer
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

Review 4.  Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.

Authors:  F Meyer; L Moore; I Bairati; L Lacombe; B Têtu; Y Fradet
Journal:  J Urol       Date:  1999-12       Impact factor: 7.450

5.  4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.

Authors:  C C Schulman; F M Debruyne; G Forster; F P Selvaggi; A R Zlotta; W P Witjes
Journal:  Eur Urol       Date:  2000-12       Impact factor: 20.096

6.  Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.

Authors:  S L Goldenberg; L H Klotz; J Srigley; M A Jewett; D Mador; Y Fradet; J Barkin; J Chin; J M Paquin; M J Bullock; S Laplante
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

7.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

Authors:  M S Soloway; R Sharifi; Z Wajsman; D McLeod; D P Wood; A Puras-Baez
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

8.  [Laparoscopic radical prostatectomy. Preliminary evaluation after 28 interventions].

Authors:  B Guillonneau; X Cathelineau; E Barret; F Rozet; G Vallancien
Journal:  Presse Med       Date:  1998-10-17       Impact factor: 1.228

9.  Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.

Authors:  Isaac J Powell; Catherine M Tangen; Gary J Miller; Bruce A Lowe; Gabriel Haas; Peter R Carroll; Michael B Osswald; Ralph DeVERE WHITE; Ian M Thompson; E David Crawford
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

10.  Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China.

Authors:  F L Gu; T L Xia; X T Kong
Journal:  Urology       Date:  1994-11       Impact factor: 2.649

View more
  9 in total

1.  Laparoscopic radical cystectomy with orthotopic gastric neobladder: technique and initial outcomes.

Authors:  Xing-Huan Wang; Xiao-Yong Pu; Huai-Peng Wang; Li-Quan Hu
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-03       Impact factor: 4.553

2.  Modified apical dissection of the prostate improves early continence in laparoscopic radical prostatectomy: technique and initial results.

Authors:  Xin Gao; Ke-Bing Wang; Xiao-Yong Pu; Xiang-Fu Zhou; Jian-Guang Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-23       Impact factor: 4.553

3.  Single-centre study comparing standard apical dissection with a modified technique to facilitate vesico-urethral anastomosis during laparoscopic radical prostatectomy.

Authors:  Xin Gao; Xiao-Yong Pu; Jie Si-Tu; Wen-Tao Huang
Journal:  Asian J Androl       Date:  2011-02-07       Impact factor: 3.285

Review 4.  Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis.

Authors:  Zhi-Rui Zhou; Xiao-Dong Zhu; Jun Xia; Zhang-Yu Zou; Song Qu; Xian-Tao Zeng; Zhi Mao; Zhong-Guo Liang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-05       Impact factor: 4.553

5.  Neoadjuvant hormonal therapy preceding radical prostatectomy for clinically localized prostate cancer: early postoperative complications and biochemical recurrence.

Authors:  Seung Woo Yang; Ki Hak Song; Jae Sung Lim; Chong Koo Sul
Journal:  Korean J Urol       Date:  2011-01-24

6.  Laparoscopic radical prostatectomy: oncological and functional results of 126 patients with a minimum 3-year follow-up at a single Chinese institute.

Authors:  Xin Gao; Jian-Hua Zhou; Liao-Yuan Li; Jian-Guang Qiu; Xiao-Yong Pu
Journal:  Asian J Androl       Date:  2009-08-03       Impact factor: 3.285

7.  Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.

Authors:  Krishan R Jethwa; Keith M Furutani; Lance A Mynderse; Torrence M Wilson; Richard Choo; Bernard F King; Eric Bergstralh; Brian J Davis
Journal:  J Contemp Brachytherapy       Date:  2016-11-04

8.  Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy.

Authors:  Taku Naiki; Noriyasu Kawai; Takehiko Okamura; Daisuke Nagata; Yoshiyuki Kojima; Hidetoshi Akita; Takahiro Yasui; Keiichi Tozawa; Kenjiro Kohri
Journal:  BMC Urol       Date:  2012-12-18       Impact factor: 2.264

9.  The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients With Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis.

Authors:  Lijin Zhang; Hu Zhao; Bin Wu; Zhenlei Zha; Jun Yuan; Yejun Feng
Journal:  Front Oncol       Date:  2021-02-08       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.